Your shopping cart is currently empty

AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. It blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $536 | - | In Stock | |
| 10 mg | $909 | - | In Stock |
| Description | AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. It blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo[1]. |
| In vitro | AS-99 TFA was tested against 20 histone methyltransferases, including NSD1, NSD2, NSD3, and SETD2, revealing no significant inhibition at 50 μM, indicating over 100-fold selectivity towards ASH1L[1]. AS-99 TFA affects the growth of MLL leukemia cells (MV4;11, MOLM13, KOPN8, RS4;11) with GI50 values ranging from 1.8 μM to 3.6 μM[1]. AS-99 TFA (1-8 μM; 7 days) also induces apoptosis in MLL leukemia cells, but not in K562 cells, as shown by Annexin V positive cell quantification, and it suppresses MLL fusion driven transcriptional programs[1]. |
| In vivo | AS-99 (30 mg/kg; i.p.; q.d., treated for 14 consecutive days) TFA reduces leukemia burden in mice[1].AS-99 TFA is used for in vivo studies in mice, which reveals favorable exposure in plasma upon i.v. and i.p. administration (AUC = 9701 hr* ng/mL and 10,699 hr* ng/mL, respectively), suitable half-life (~5-6 h) and Cmax >10 μM[1]. |
| Molecular Weight | 707.71 |
| Formula | C29H31F6N5O5S2 |
| Cas No. | 3115178-55-4 |
| Smiles | O=C(O)C(F)(F)F.O=C(NCC=1C=CC=2C(=CN(C2C1)C3CCN(CC3)S(=O)(=O)C(F)(F)F)C=4C=CC=C(C4)C(=S)N)C5CN(C)C5 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250.00 mg/mL (353.25 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.30 mg/mL (4.66 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.